Literature DB >> 26645736

Role of Aspirin and Dexamethasone against Experimentally Induced Depression in Rats.

Shailendra Bhatt1, Priyanka Shukla1, Jibril Raval1, Sunita Goswami2.   

Abstract

A large number of current studies indicate that inflammatory mediators may contribute to depression in experimental models as well as in human beings. Nevertheless, the subject, whether anti-inflammatory treatments can prevent depression still remains controversial. In the present study, a chronic mild stress (CMS) model of male Sprague Dawley rats was used to investigate the role of anti-inflammatory drugs in the treatment of depression. All the animals in different groups, except the normal control group, were exposed to CMS procedure for 28 days and concurrently treated with aspirin (10 mg/kg, p.o.), dexamethasone (1 mg/kg p.o.) and amitriptyline (10 mg/kg p.o., reference standard), respectively. Amitriptyline was also used in combination with aspirin and dexamethasone to inspect any synergistic effects. Tests performed towards the end of the study included sucrose preference test, behavioural tests like forced swim test, elevated plus-maze, light/dark box, locomotor activity and biochemical estimations like serum cortisol and brain neurotransmitters. Disease control group (CMS-treated) produced significant depressive behaviour in rats. The animals treated with aspirin showed increased sucrose preference, decreased immobility time in forced swim test, decreased serum cortisol and increased brain serotonin levels signifying antidepressant action. In contrast, there was aggravation of depressive behaviour in rats treated with dexamethasone. Together, these findings suggest that aspirin can serve as a potential antidepressant both individually and as adjunctive agent in the treatment of depression. Inhibition of the inflammatory mediators during stress procedures or any other potential physiological and biochemical mechanisms may be involved in its antidepressant effect.
© 2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26645736     DOI: 10.1111/bcpt.12539

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  5 in total

1.  The effects of a combination of intravenous dexamethasone and ketamine on postoperative mood in patients undergoing laparoscopically assisted-gynecologic surgery.

Authors:  Cheol Lee; Juhwan Lee; Gilho Lee; Hayeong Lee; Zhou Shicheng; Jihyo Hwang
Journal:  Psychopharmacology (Berl)       Date:  2018-06-14       Impact factor: 4.530

Review 2.  Targeting inflammation: a potential approach for the treatment of depression.

Authors:  Shvetank Bhatt; Thangaraj Devadoss; Niraj Kumar Jha; Moushumi Baidya; Gaurav Gupta; Dinesh Kumar Chellappan; Sachin Kumar Singh; Kamal Dua
Journal:  Metab Brain Dis       Date:  2022-10-14       Impact factor: 3.655

3.  Protective effect of aspirin treatment on mouse behavior in the acute phase of experimental infection with Trypanosoma cruzi.

Authors:  Arturo Silvero-Isidre; Sergio Morínigo-Guayuán; Aaron Meza-Ojeda; Marcelo Mongelós-Cardozo; Claudia Centurión-Wenninger; Susy Figueredo-Thiel; Diego F Sanchez; Nidia Acosta
Journal:  Parasitol Res       Date:  2017-12-01       Impact factor: 2.289

Review 4.  The Impact of Immunological Factors on Depression Treatment - Relation Between Antidepressants and Immunomodulation Agents.

Authors:  Jovana Vojvodic; Goran Mihajlovic; Petar Vojvodic; Dusan Radomirovic; Aleksandra Vojvodic; Tatjana Vlaskovic-Jovicevic; Zorica Peric-Hajzler; Dusica Matovic; Sanja Dimitrijevic; Goran Sijan; Maria Grazia Roccia; Massimo Fioranelli; Torello Lotti
Journal:  Open Access Maced J Med Sci       Date:  2019-09-12

Review 5.  The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.

Authors:  Esmé Jansen van Vuren; Stephan F Steyn; Christiaan B Brink; Marisa Möller; Francois P Viljoen; Brian H Harvey
Journal:  Biomed Pharmacother       Date:  2021-01-01       Impact factor: 6.529

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.